Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary…
Reported First Quarter Revenue of $21.2 millionGenerated Adjusted EBITDA from Operations of $0.5 millionContinued Execution of Integrated Healthcare Platform Strategy…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian…
CLEVELAND, OHIO, May 15, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public…
May 15, 2026 20:23 ET | Source: Constellation Software Inc. TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc.…
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage…
May 15, 2026 09:00 ET | Source: Vaso Corporation PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”)…
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the first…
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and…
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome…